DHA (Docosahexaenoic Acid) — Competitive Intelligence Brief

DHA (Docosahexaenoic Acid) (DHA (Docosahexaenoic Acid)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Omega-3 polyunsaturated fatty acid. Area: Neurology.

phase 3 Omega-3 polyunsaturated fatty acid Neurology Small molecule

Target snapshot

DHA (Docosahexaenoic Acid) (DHA (Docosahexaenoic Acid)) — Alzheimer's Disease Cooperative Study (ADCS). DHA is an omega-3 polyunsaturated fatty acid that supports neuronal membrane integrity and reduces neuroinflammation in the brain.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DHA (Docosahexaenoic Acid) TARGET	DHA (Docosahexaenoic Acid)	Alzheimer's Disease Cooperative Study (ADCS)	phase 3	Omega-3 polyunsaturated fatty acid
Ethyl Eicosapentaenoic Acid	Ethyl Eicosapentaenoic Acid	New York State Psychiatric Institute	marketed	Omega-3 polyunsaturated fatty acid
Fish oils	Fish oils	The University of Western Australia	phase 3	Omega-3 polyunsaturated fatty acid supplement
Omega-3 supplements	Omega-3 supplements	University of Pennsylvania	phase 3	Dietary supplement / Omega-3 polyunsaturated fatty acid

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Omega-3 polyunsaturated fatty acid class)

1. Alzheimer's Disease Cooperative Study (ADCS) · 1 drug in this class
2. New York State Psychiatric Institute · 1 drug in this class